Selecting the Appropriate Plasma pTau217 Assay for Clinical Use

Overview

Plasma pTau217 assays demonstrate excellent accuracy in detecting Alzheimer's disease pathology, with the %pTau217WashU mass spectrometry-based assay showing superior performance. Immunoassays offer scalable alternatives with varying accuracy, highlighting the need to balance assay performance with practical clinical deployment.

Background

Alzheimer’s disease diagnosis has been revolutionized by blood-based biomarkers, particularly plasma pTau217, which reflects amyloid-β and tau brain deposition and predicts cognitive decline. Multiple assays have emerged, including mass spectrometry and immunoassays, each with distinct advantages and limitations. Accurate and scalable plasma biomarkers are critical for early diagnosis and patient stratification in clinical trials.

Data Highlights

Key Findings

• All plasma pTau217 assays showed excellent diagnostic performance with AUCs between 0.91 and 0.96 for Aβ-PET classification.
• The %pTau217WashU assay outperformed all other plasma assays and FDA-approved CSF biomarkers in accuracy, sensitivity, and specificity for Aβ-PET positivity.
• Mass spectrometry assays, while highly accurate, require expensive equipment and specialized personnel, limiting scalability.
• Immunoassays such as pTau217Lilly and pTau217ALZpath offer more scalable and cost-effective options but with slightly lower accuracy.
• Plasma pTau217Janssen showed poorer performance compared to FDA-approved CSF biomarkers for Aβ-PET detection.
• Plasma biomarkers continued to increase with higher amyloid pathology levels, unlike CSF biomarkers which plateaued.

Clinical Implications

Clinicians should consider the trade-off between assay accuracy and practical feasibility when selecting plasma pTau217 assays. Mass spectrometry-based %pTau217WashU is ideal for small-scale, high-accuracy testing, whereas immunoassays provide scalable options suitable for broader clinical screening. Plasma biomarkers may offer superior monitoring of disease progression compared to CSF biomarkers, supporting their use in patient stratification and clinical trials.

Conclusion

Plasma pTau217 assays represent a transformative advance in Alzheimer’s disease diagnostics, with the %pTau217WashU assay leading in accuracy. Balancing assay performance with accessibility will be key to integrating these biomarkers into routine clinical practice.

References

1. Warmenhoven et al. 2021 -- A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
2. Pilotto et al. 2021 -- Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison